Get Immunic alerts: Several other research firms have also recently commented on IMUX. William Blair began coverage on shares of Immunic in a research report on Tuesday, March 25th. They issued an ...

D. Boral Capital restated a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Thursday, April 10th. William Blair began coverage on shares of Immunic in a ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s shares closed last Friday at $1.20. Discover the ...

Fintel reports that on April 21, 2025, William Blair initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Investing.com -- William Blair initiated coverage of Zillow Group Inc (NASDAQ:ZG). with a Market Perform rating, citing the company’s dominant position in online home search but warning of ...

Fintel reports that on April 8, 2025, William Blair initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform recommendation. As of April 2, 2025, the average one-year price ...